Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II one arm study. Patients with HER2 (Human Epidermal Growth Factor Receptor
2)positive early stage breast cancer will receive ABI-007 and vinorelbine in combination with
trastuzumab before having breast surgery.